Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies

Drug Discovery Today

Volumn 12, Issue 11-12, 2007, Pages 472-478

  Fitzgerald, Mary F ^a   Fox, J Craig ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CARMOTEROL; CICLESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 159797; GSK 159802; GSK 233705; GSK 59790; GSK 597901; GSK 656398; GSK 678007; GSK 96108; GW 642444; INDACATEROL; IPRATROPIUM BROMIDE; LAS 34273; LAS 35201; MOMETASONE FUROATE; MUSCARINIC M3 RECEPTOR ANTAGONIST; NVA 327; NVD 237; QAT 370; SALBUTAMOL; SALMETEROL; STEROID; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNDACATEROL;

AIRWAY OBSTRUCTION; ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; HEALTH STATUS; HUMAN; MONOTHERAPY; MORTALITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SINGLE DRUG DOSE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 34249054459     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.04.003     Document Type: Review

References (53)

1. Halbert R.J., et al. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28 (2006) 523-532
2. Lokke A., et al. Developing COPD: a 25 year follow up study of the general population. Thorax 61 (2006) 935-939
3. Anzueto A., et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 18 (2005) 75-81
4. Sapey E., and Stockley R.A. COPD exacerbations 2: aetiology. Thorax 61 (2006) 250-258
5. Donaldson G.C., and Wedzicha J.A. COPD exacerbations 1: epidemiology. Thorax 61 (2006) 164-168
6. Fabbri L., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 1 (2004) 105-141
7. Connors Jr. A.F., et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 154 (1996) 959-967
8. Ai-Ping C., et al. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 128 (2005) 518-524
9. Hanania N.A., et al. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm. Pharmacol. Ther. 18 (2005) 19-22
10. Koumis T., and Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin. Ther. 27 (2005) 377-392
11. Ferguson G.T. Why does the lung hyperinflate?. Proc. Am. Thorac. Soc. 3 (2006) 176-179
12. Casaburi R., and Porszasz J. Reduction of hyperinflation by pharmacologic and other interventions. Proc. Am. Thorac. Soc. 3 (2006) 185-189
13. Tashkin D.P., and Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004) 249-259
14. Barr R.G., et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61 (2006) 854-862
15. Salpeter S.R., et al. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J. Gen. Intern. Med. 21 (2006) 1011-1019
16. Nelson H.S., et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
17. Martinez F.D. Safety of long-acting beta-agonists-an urgent need to clear the air. N. Engl. J. Med. 353 (2005) 2637-2639
18. Calverley P.M. The role of corticosteroids in chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 26 (2005) 235-245
19. Highland K.B., et al. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med. 138 (2003) 969-973
20. Sin D.D., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 (2005) 992-997
21. Gartlehner G., et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann. Fam. Med. 4 (2006) 253-262
22. Suissa S. Statistical treatment of exacerbations in therapeutic trials of COPD. Am. J. Respir. Crit. Care Med. 173 (2006) 842-846
23. Calverley P.M. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1 (2004) 121-124
24. Calverley P., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
25. Szafranski W., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21 (2003) 74-81
26. Calverley P.M., et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22 (2003) 912-919
27. Calverley P.M., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356 (2007) 775-789
28. Gan W.Q., et al. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm. Med. 5 (2005) 3
29. Leigh R., et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 166 (2002) 1212-1217
30. Barnes N.C., et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 173 (2006) 736-743
31. Hattotuwa K.L., et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. J. Respir. Crit. Care Med. 165 (2002) 1592-1596
32. Dusser D., et al. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 27 (2006) 547-555
33. Cooper N., et al. NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model. Eur. Respir. J. 28 (2006) 436s
34. Gunawardena K.A., et al. NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease. Eur. Respir. J. 28 (2006) 527s
35. Singh D., et al. NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD. Eur. Respir. J. 28 (2006) 527s
36. Thomas R., et al. Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans. Eur. Respir. J. 28 (2006) 661s
37. Lu S., et al. An oral selective M3 anticholinergic receptor antagonist in COPD. Eur. Respir. J. 28 (2006) 772-780
38. Rennard S.I., et al. Indacaterol, a novel once-daily beta2-agonist, provides 24-Hour bronchodilator efficacy in moderate-to-severe COPD. Proc. Am. Thorac. Soc. 3 (2006) A117
39. Hanrahan J.P., et al. Efficacy and safety of arformoterol in COPD: a prospective Phase 3 clinical trial. Proc. Am. Thorac. Soc. 3 (2006) A847
40. Baumgartner R.A., et al. A crossover dose-ranging study of arformoterol in patients with COPD. Proc. Am. Thorac. Soc. 3 (2006) A847
41. Colice G.L. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin. Pharmacother. 7 (2006) 2107-2117
42. Nevin B.J., and Broadley K.J. Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. Pulm. Pharmacol. Ther. 17 (2004) 219-232
43. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105 (1994) 1411-1419
44. Cazzola M., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 17 (2004) 35-39
45. Cazzola M., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. 98 (2004) 1214-1221
46. Baloira Villar A., and Vilarino P.C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch. Bronconeumol. 41 (2005) 130-134
47. van Noord J.A., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26 (2005) 214-222
48. Sequeira, J.A. and Yang, T. Schering Corporation (2006) Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist, WO/2006/105401
49. Cazzola M., et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. (2006) PMID: 16807023 [Epub ahead of print]
50. Aaron S.D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. (2007) PMID: 17310045 [Epub ahead of print]
51. Lundback B., et al. Not 15 but 50% of smokers develop COPD? Report from the obstructive lung disease in northern Sweden studies. Respir. Med. 97 (2003) 115-122
52. Sandford A.J., and Silverman E.K. Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax 57 (2002) 736-741
53. Pauwels R.A., and Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364 (2004) 613-620